SynthesisBioMed research international2020
Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis.
Synthesis in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis.BMC cancer · 2021Pooled it
- Circular RNA hsa_circ_0006522 correlates with unfavorable prognosis and promotes the proliferative, migrative, and invasive abilities of breast cancer cells.Translational cancer research · 2025Article
- CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities.Journal of translational medicine · 2024Review
- Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.Frontiers in oncology · 2023Article
- Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022Review
- Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.Molecular therapy. Nucleic acids · 2022Review
- Review
- The Use of circRNAs as Biomarkers of Cancer.Methods in molecular biology (Clifton, N.J.) · 2021Review
- The Circular RNA-miRNA Axis: A Special RNA Signature Regulatory Transcriptome as a Potential Biomarker for OSCC.Molecular therapy. Nucleic acids · 2020Review
- The Emerging Picture of the Roles of CircRNA-CDR1as in Cancer.Frontiers in cell and developmental biology · 2020Review
- Prognostic and Diagnostic Significance of circRNA Expression in Esophageal Cancer: A Meta-analysis.Gastroenterology research and practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy.
resultsThis meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50-3.15,
conclusionsHigh expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.